Teclison develops innovative cancer therapies designed to induce tumor necrosis and enhance antitumor immunity in solid cancers. Their platform remodels the tumor immune microenvironment to improve patient response to existing immunotherapies. The company's pipeline focuses on enhancing immune checkpoint inhibitors for patients with metastatic solid tumors.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing immunotherapies often fail to elicit strong responses in patients with solid tumors, particularly when the cancer has metastasized to the liver. The tumor microenvironment in these cases can suppress immune cell activity, limiting the effectiveness of treatments like immune checkpoint inhibitors.
Solution
The company is developing liver-directed therapies designed to induce necrosis specifically in liver metastatic lesions, leading to a significant reduction in tumor volume. By triggering controlled cell death within the tumor, these therapies aim to remodel the tumor immune microenvironment and enhance antitumor immunity. This approach seeks to overcome the limitations of current immunotherapies and improve treatment outcomes for cancer patients with solid tumors that have spread to the liver. The goal is to unlock the potential for long-term remission by making these tumors more susceptible to immune-mediated destruction.
Target Audience
The primary target audience includes cancer patients with solid tumors that have metastasized to the liver, as well as oncologists and researchers seeking to improve outcomes for these patients.
Features
- Liver-directed drug delivery for targeted necrosis of metastatic lesions
- Modulation of the tumor microenvironment to promote immune cell infiltration and activation
- Enhancement of immune checkpoint inhibitor efficacy
- Development of therapies for solid tumors that have metastasized to the liver